Loading...
Please wait, while we are loading the content...
Similar Documents
Effectiveness of Carbapenems in Hospital Acquired Pneumonia and Ventilator Associated Pneumonia against Extended Spectrum β-lactamases Enzyme producing Enterobacteriaceae in a Tertiary Care Hospital
| Content Provider | Semantic Scholar |
|---|---|
| Author | Naz, Afreen Sultana, Sabha Begum, S. Sadiqa Baig, Mr Mirza Misba Ali Mahmood, Syed Faisal |
| Copyright Year | 2019 |
| Abstract | Background: This study aims to find out the prevalence of HAP/VAP, risk factors implicated, organisms involved and their sensitivity patterns. This study was designed to improve morbidity and reduce the hospital stay. Objective: The aim was to describe clinical response and microbiologic cure rates associated with carbapenems as first line treatment for infections caused by ESBL-producing organisms. Methodology: A prospective cohort observational open labelled study was conducted at Owaisi Hospital and Research Center, for patients admitted in the Department of Pulmonology for a period of six months. The demographic data, diagnostic criteria, associated risk factors and laboratory data including culture and antimicrobial susceptibility were collected. Results: The total in patient population in pulmonolgy department was 150, out of which 30 were affected by nosocomial pneumonia. Among total patients (i.e n=30) The prevalence of HAP was found to be 19(63.3%) and VAP was found to be 11(36.6%).The incidence of ESBLS Organisms were higher in female patients than in male patients. The culprit ESBLS which are responsibe for HAP & VAP were klebsiella (47%),E.coli (17%) citrobacter (23%), pseudomonas (13%).HTN (90%),DM (87%),were most commonly occurring comorbidities. We analyzed the clinical cure rates according to the data collected ie out of 30 pneumonia patients: 25 showed improvement ( 83%), mortality seen in 3 VAP patients (10%), 2 patients (6.6%) doesn’t showed any improvement. Conclusion: The Prevalence of HAP/VAP was 12.6% (HAP), 7.3%(VAP) out of 150 admissions in pulmonology dept. This study highlights the progressive rise of broad resistance, ever-increasing prevalent and diversity of blactamases in Enterobacteriaceae members is driving to the use of carbapenems as a first line therapy |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://iosrjournals.org/iosr-jpbs/papers/Vol14-issue4/Series-2/I1404025872.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
